A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer

J. A. Lorente, O. Arango, O. Bielsa, R. Cortadellas, J. Lloreta-Trull, A. Gelabert-Mas

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Objectives: To analyse tumour volume (TV) in clinically localised prostate cancer patients treated with neo-adjuvant combined androgen blockade (CAB) therapy prior to radical prostatectomy. Patients and Methods: Two hundred consecutive patients treated between 1996 and 2000 were retrospectively analysed. Fifty patients underwent radical prostatectomy alone and 45 were treated with CAB for 1-3 months, 83 for 4-6 months and 22 for more than 6 months before surgery. Logistic regression analysis was performed to identify the strongest independent prognosticator of organ-confined disease. Results: No evidence of residual cancer was found in 11 specimens (5.6%). Regarding TV, 20 specimens showed less than 0.1 cc, 33 between 0.1 and 0.49 cc and 86 more than 0.5 cc. Smaller TV was found in CAB-treated patients. Significant correlation was observed between treatment duration and TV. In logistic regression analysis, only CAB duration and TV were significantly correlated with organ-confined disease. Conclusions: Prominent regressive features and lower TV were found after neo-adjuvant CAB. It seems that more prolonged treatment may lead to greater tumoural regression. Only tumour burden and length of CAB therapy were independent variables significantly correlated with pathologically localised prostate cancer. © 2002 Elsevier Science B.V. All rights reserved.
Original languageEnglish
Pages (from-to)119-123
JournalEuropean Urology
Volume43
Issue number2
DOIs
Publication statusPublished - 1 Feb 2003

Keywords

  • Combined androgen blockade
  • Neo-adjuvant therapy
  • Prostate cancer
  • Tumour volume

Fingerprint Dive into the research topics of 'A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer'. Together they form a unique fingerprint.

  • Cite this